MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • MDS Virtual Congress 2020

    Is early-onset of levodopa-induced dyskinesia a predictor of GBA mutation? A next-generation sequencing study of young-onset Parkinson’s disease patients in Thailand

    S. Thanprasertsuk, P. Phowthongkum, T. Hopetrungraung, C. Poorirerngpoom, T. Satirapatya, P. Wichit, O. Phokaewvarangkul, K. Vongpaisarnsin, S. Bongsebandhu-phubhakdi, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To examine the prevalence of genetic causes in young-onset Parkinson’s disease (YOPD) patients with levodopa-induced dyskinesia (LID) in Thailand using a next-generation sequencing (NGS)…
  • MDS Virtual Congress 2020

    Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

    C. Tanner, D. Chernick, A. Formella (San Francisco, CA, USA)

    Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…
  • MDS Virtual Congress 2020

    Persistent head dyskinesias following STN DBS in Parkinson’s disease resolve using directionality

    C. vander Linden, C. Bogaert-Miclaus, D. Colle (Ghent, Belgium)

    Objective: To control subthalamic nucleus deep brain stimulation (STN DBS) induced dyskinesias in Parkinson's disease (PD) using directionality. Background: Levodopa-induced dyskinesias (LID) frequently occur in…
  • MDS Virtual Congress 2020

    Intrinsic brain functional connectivity predicts treatment-related motor complications in drug-naive Parkinson’s disease patients

    R. De Micco, F. Di Nardo, M. Siciliano, G. Caiazzo, F. Esposito, G. Tedeschi, A. Tessitore (Naples, Italy)

    Objective: Using resting-state functional MRI, we investigated intrinsic brain networks connectivity at baseline in a cohort of drug-naïve Parkinson’s disease (PD) patients which successively developed treatment-related…
  • MDS Virtual Congress 2020

    Opicapone in fluctuating Parkinson’s disease: The daily clinical practice

    L. Armengou Garcia, G. Martí-Andrés, R. Valentí Azcárate, I. Esparragosa Vázquez, C. Toledano Illán, R. Villino Boquete, R. Luquin (Pamplona, Spain)

    Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…
  • MDS Virtual Congress 2020

    Home videos made on smart phone supplements paper based diary for correct identification of Motor states in Parkinson’s disease

    D. Dash, R. Singh, D. Vibha, M. Tripathi (Delhi, India)

    Objective: We aimed to assess the feasibility of home videos made on smart phone as a supplemental tool to paper based diary in registering the…
  • MDS Virtual Congress 2020

    Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias

    C.T Gan, M. Wang, QQ. Si, Y.S Yuan, Y. Zhi, L.N Wang, K.W Ma (Nanjing, China)

    Objective: Our investigation aimed to explore interhemispheric functional alterations and its corresponding morphological synchronization changes. Background: Levodopa-induced dyskinesias are common motor complication of Parkinson’s disease…
  • MDS Virtual Congress 2020

    Combined therapy VS only levodopa therapy in a 5-years follow up cohort

    C. Borrue-Fernandez, J. Alvarez -Alberca (San Sebastian Reyes, Spain)

    Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…
  • MDS Virtual Congress 2020

    Real-World Evidence for a Smartwatch-based Parkinson’s Motor Assessment App in Patients Undergoing Therapy Changes

    A. Hadley, D. Riley, D. Heldman (Cleveland, OH, USA)

    Objective: We sought to investigate patient and clinician usability of a smartwatch-based wearable motor assessment system for measuring Parkinson’s disease (PD) motor symptoms in patients undergoing…
  • 2019 International Congress

    Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product

    R. Hauser, S. Isaacson, A. Mittur, A. Formella, R. Patni (Tampa, FL, USA)

    Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley